Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials
Journal of the Saudi Heart Association · 19.06.2025 · 37 (3)
DOI: 10.37616/2212-5043.1439 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 19.06.2025. Verfasst von Christopher D Tristan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Central Java, Indonesia. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Olezarsen emerged as a novel promising Apo-C3 inhibitor for dyslipidemia. However, its dose-response relationship remains uncertain. This review aims to evaluate the lipid-lowering effect of olezarsen, safety measures, and dose-response effects to determine the optimal dose. A systematic search was conducted across Scopus, PubMed, ScienceDirect, and CENTRAL on January 2, 2025. Randomized controlled trial (RCT) comparing olezarsen with placebo in dyslipidemia was included. The Rob 2.0 tool was implemented to assess quality. R-studio and STATA were used to conduct statistical analysis. From a total of 194 documents at initial search, four RCTs involving 361 patients were included in the present analysis. Olezarsen significantly reduces plasma Apo-C3 across all dosage cohorts, including a 50 mg dose (MD: -70.31%; 95% CI: -83.89 to -56.74; p < 0.01) and an 80 mg dose administered every four weeks. It also significantly lowered triglycerides at any dose level, with reductions observed at 50 mg (MD: -49.84%; 95% CI = -70.42 to -22.37; p = 0) and 80 mg (MD: -52.32%; 95% CI: -58.25 to -46.40; p < 0.01). Olezarsen has minimal effect on low-density lipoprotein (LDL) but significantly increases high-density lipoprotein (HDL). Dose-response meta-analysis modeling suggests that 50 mg administered every four weeks may represent the optimal dose, beyond which added benefits diminish. Safety analysis revealed tolerability in liver, renal, and hematological parameters. In conclusion, olezarsen is an effective Apo-C3 inhibitor that improves lipid profiles with a favorable safety profile. This modeling-based insight refines previous findings by delineating a clearer therapeutic window
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Central Java, Indonesia.
- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Central Java, Indonesia.
- Universitas Sebelas Maret Hospital, Sukoharjo, Central Java, Indonesia.
Zitieren
APA
Tristan, C. D., Myrtha, R., Wijayanto, M. A., Kynaya, E. M., Hamka, M. F., Sudiono, N. E., Rusyidi, M. A., & Ilyas, M. F. (2025). Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Journal of the Saudi Heart Association, 37(3). https://doi.org/10.37616/2212-5043.1439
Vancouver
Tristan CD, Myrtha R, Wijayanto MA, Kynaya EM, Hamka MF, Sudiono NE, et al. Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Journal of the Saudi Heart Association. 2025;37(3). doi:10.37616/2212-5043.1439
BibTeX
@article{Tristan2025,
author = {Tristan, Christopher D and Myrtha, Risalina and Wijayanto, Matthew A and Kynaya, Erlangga M and Hamka, Muhammad F and Sudiono, Nathania E and Rusyidi, Muhammad A and Ilyas, Muhana F},
title = {Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials},
journal = {Journal of the Saudi Heart Association},
year = {2025},
volume = {37},
number = {3},
doi = {10.37616/2212-5043.1439}
}
EUVIMED